Friday, May 6, 2011

Chrissie Fletcher, Director and Head of Biostatistics of Amgen International, in collaboration with Pharma IQ presents the path to health technology assessment

Chrissie Fletcher discusses Pharma IQ of health technology assessment (HTA​​, Health Technology Assessment). In this podcast he explained in his comprehensive  vision of  the future  in relation  to the interaction between economists and statesmen in the health field, has identified the reason why so much emphasis  is placed on the preparation  of reports for reimbursement  and has indicated its outlook  on trend in the coming  years  by pharmaceutical companies to test more frequently to perform this task internally.

According to Mrs. Fletcher, the preparation of reports for reimbursements is playing an increasingly important role, because it represents the basis for all programs of clinical trials, the evidence that will attempt to demonstrate the clinical efficacy of the products and their safety, in addition to their economic advantage.

The original text of this announcement in the language of departure is the official version prevails. The translations are provided solely for the convenience of the reader and must return to the original text, which is the only legally valid.

No comments:

Post a Comment